Regnum Corp. (OTCPK: RGMP)
Health Care · Pharmaceuticals · US
$—
— today · — 1Y
Regnum Corp. (OTCPK: RGMP) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $23.00 and employs 1 people.
trading between 0.00 and 0.50.
Tweenvest scores Regnum Corp. across four factors: quality 21/100. Its strongest factor is quality.
RGMP price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $23.00
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.03
- Dividend yield
- —
- Beta (5Y)
- -0.81
- 52-week high
- $0.50
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 22.95M
- Employees
- 1
- Next earnings
- —
About Regnum Corp.
Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody CC chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. The company was incorporated in 2016 and is based in New York, New York.
- ISIN
- US75915R1068
- Founded
- 2016
- Listed since
- May 29, 2019
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,253.76 | +0.55% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $272.84 | -0.07% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $154.06 | +2.26% |
| Roche Holding AGSWX: ROP | $368.80B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.38 | +1.47% |
Figures last refreshed Aug 18, 2026.